| dbo:abstract |
Tenapanor, used in form of tenapanor hydrochloride and sold under the brand name Ibsrela, is a treatment for adults with a disease of the gut called irritable bowel syndrome with constipation commonly referred to as IBS-C. Tenapanor is a drug developed by Ardelyx, which acts as an inhibitor of the sodium-proton exchanger NHE3. This antiporter protein is found in the kidney and intestines, and normally acts to regulate the levels of sodium absorbed and secreted by the body. When administered orally, tenapanor selectively inhibits sodium uptake in the intestines, limiting the amount absorbed from food, and thereby reduces levels of sodium in the body. This may make it useful in the treatment of chronic kidney disease and hypertension, both of which are exacerbated by excess sodium in the diet. It was approved for medical use in the United States in 2019. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. (en) Тенапанор — лекарственный препарат для лечения синдрома раздражённого кишечника с запорами. Одобрен для применения: США (2019). (ru) |
| dbo:alternativeName |
Ibsrela (en) |
| dbo:casNumber |
1234423-95-0 |
| dbo:chEMBL |
3304485 |
| dbo:drugbank |
DB11761 |
| dbo:fdaUniiCode |
WYD79216A6 |
| dbo:kegg |
D11652 |
| dbo:pubchem |
71587953 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Tenapanor.svg?width=300 |
| dbo:wikiPageExternalLink |
https://druginfo.nlm.nih.gov/drugportal/name/tenapanor |
| dbo:wikiPageID |
42348707 (xsd:integer) |
| dbo:wikiPageLength |
7897 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1095778763 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Antiporter dbr:Hypertension dbr:United_States_National_Library_of_Medicine dbr:Oral_administration dbr:Constipation dbr:Irritable_bowel_syndrome dbr:Food_and_Drug_Administration dbr:Chronic_kidney_disease dbc:Drugs_acting_on_the_gastrointestinal_system_and_metabolism dbr:Sodium dbr:First-in-class_medication dbr:Sodium–hydrogen_antiporter_3 |
| dbp:atcPrefix |
A06 (en) |
| dbp:atcSuffix |
AX08 (en) |
| dbp:c |
50 (xsd:integer) |
| dbp:casNumber |
1234423 (xsd:integer) |
| dbp:chembl |
3304485 (xsd:integer) |
| dbp:chemspiderid |
32056950 (xsd:integer) |
| dbp:cl |
4 (xsd:integer) |
| dbp:class |
NHE3 inhibitors (en) |
| dbp:dailymedid |
Tenapanor (en) |
| dbp:drugbank |
DB11761 (en) |
| dbp:h |
66 (xsd:integer) |
| dbp:iupacName |
N,N'-bis (en) |
| dbp:kegg |
D11652 (en) |
| dbp:legalCa |
Rx-only (en) |
| dbp:legalUs |
Rx-only (en) |
| dbp:n |
8 (xsd:integer) |
| dbp:o |
10 (xsd:integer) |
| dbp:pubchem |
71587953 (xsd:integer) |
| dbp:routesOfAdministration |
dbr:Oral_administration |
| dbp:s |
2 (xsd:integer) |
| dbp:smiles |
CN1C[C@H]C3=CCSNCCOCCOCCNCNCCCCNCNCCOCCOCCNSC4=CC=CC[C@@H]5CNC (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
DNHPDWGIXIMXSA-CXNSMIOJSA-N (en) |
| dbp:synonyms |
tenapanor hydrochloride (en) |
| dbp:tradename |
Ibsrela (en) |
| dbp:unii |
WYD79216A6 (en) |
| dbp:width |
300 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:Gastrointestinal-drug-stub dbt:Cite_web dbt:Infobox_drug dbt:Portal_bar dbt:Reflist dbt:Use_dmy_dates dbt:Fdacite dbt:Drugs.com dbt:Laxatives |
| dcterms:subject |
dbc:Drugs_acting_on_the_gastrointestinal_system_and_metabolism |
| gold:hypernym |
dbr:Drug |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:Agent114778436 yago:CausalAgent100007347 yago:Drug103247620 yago:Matter100020827 yago:PhysicalEntity100001930 dbo:Drug yago:Substance100020090 yago:WikicatDrugsActingOnTheGastrointestinalSystemAndMetabolism |
| rdfs:comment |
Тенапанор — лекарственный препарат для лечения синдрома раздражённого кишечника с запорами. Одобрен для применения: США (2019). (ru) Tenapanor, used in form of tenapanor hydrochloride and sold under the brand name Ibsrela, is a treatment for adults with a disease of the gut called irritable bowel syndrome with constipation commonly referred to as IBS-C. It was approved for medical use in the United States in 2019. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. (en) |
| rdfs:label |
Tenapanor (en) Тенапанор (ru) |
| owl:sameAs |
freebase:Tenapanor yago-res:Tenapanor wikidata:Tenapanor dbpedia-ru:Tenapanor https://global.dbpedia.org/id/fVUe |
| prov:wasDerivedFrom |
wikipedia-en:Tenapanor?oldid=1095778763&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Tenapanor.svg |
| foaf:isPrimaryTopicOf |
wikipedia-en:Tenapanor |
| is dbo:wikiPageRedirects of |
dbr:Ibsrela dbr:Tenapanor_hydrochloride |
| is dbo:wikiPageWikiLink of |
dbr:ATC_code_A06 dbr:Ibsrela dbr:Tenapanor_hydrochloride dbr:Sodium–hydrogen_antiporter_3 |
| is foaf:primaryTopic of |
wikipedia-en:Tenapanor |
